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An isolated polynucleotide molecule includes a DNA 
sequence encoding an infectious RNA molecule encoding a 
modi?ed live viral strain of an Equine arteritis virus, Wherein 
the DNA sequence is SEQ ID NO:1 or a degenerate variant 
thereof. Also provided are transformed or transfected host 
cells including that sequence, vectors including the sequence, 
and isolated infectious RNA molecules encoded by the 
sequence. Further, a modi?ed DNA sequence encoding an 
infectious RNA molecule encoding a modi?ed live viral 
strain of an Equine arteritis virus is provided Wherein the 
DNA sequence is SEQ ID NO:2 or a degenerate variant 
thereof, including a silent point mutation alloWing distin 
guishing the modi?ed sequence from the parent and other 
strains of Equine arteritis virus. 
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INFECTIOUS CDNA CLONE OF THE 
MODIFIED LIVE VIRUS VACCINE STRAIN 
OF EQUINE ART ERIT IS VIRUS 
This utility patent application claims the bene?t of priority 
in US. Provisional Patent Application Ser. No. 61/156,595 
?led on Mar. 2, 2009, the entirety of the disclosure of Which 
is incorporated herein by reference. 
TECHNICAL FIELD 
The present invention relates to an infectious clone of the 
modi?ed live virus (MLV) vaccine strain of Equine arteritis 
Virus (EAV). In particular, the invention relates to an infec 
tious cDNA clone of the MLV vaccine strain allowing gen 
eration of full length, infectious transcripts of MLV EAV. Use 
of the functional, infectious recombinant virion of EAV 
derived from an attenuated vaccine strain in marker vaccines, 
companion diagnostic tests, and the like is contemplated. 
BACKGROUND OF THE INVENTION 
Equine arteritis virus (EAV) is a member of the genus 
Arlerivirus, family Arteriviridae in the order Nidovirales (Ca 
vanagh, 1997), and is the causative agent of equine viral 
arteritis (EVA) of horses (Doll et al., 1957a). Outbreaks of 
EVA are characterized by any combination of systemic illness 
of adult horses, abortion of pregnant mares, interstitial pneu 
monia of young foals and persistent infection of stallions 
(Doll et al., 1957a; Doll et al., 1957b; Golnik et al., 1981; 
Timoney et al. 1986; Timoney et al., 1987; Timoncy et al., 
1992; Carman et al., 1988; Vaala et al., 1992; Del Piero et al., 
1995; Del Piero et al., 1997). EAV is horizontally transmitted 
either by aerosol during outbreaks of EVA or venerally via the 
breeding of an infected stallion to susceptible mares, and 
vertically through congenital infection of foals born to mares 
infected late in gestation (Timoney et al., 1987; Timoney et 
al., 1992; Vaala et al., 1992; Timoney and McCollum, 1993; 
Glaser et al., 1996). 
Dissemination of EAV by fomites such as vehicles, 
tWitches, arti?cial vaginas and shanks can be an important 
source of infection in some outbreaks (Collins et al. 1987; 
Timoney and McCollum, 1988; Timoney and McCollum, 
1993). The persistently infected carrier stallion clearly plays 
an important role in perpetuation and sexual dissemination of 
EAV. The persistence of EAV in the male reproductive tract is 
testosterone-dependent (Timoney and McCollum, 1993). It 
Was recently shoWn that EAV behaves as a quasi-species 
during persistent infection of carrier stallions, With regular 
emergence of novel genotypic and phenotypic viral variants 
(Hedges et al., 1999). 
The EAV genome is 12.7 kb and contains 5' and 3' untrans 
lated regions and nine functional open reading frames [ORFs; 
(Snijder and Meulenberg, 1998. Snijder et al., 1999)]. ORFs 
1a and 1b encode tWo replicase polyproteins [pp1a and 
pp1ab; (de Vries et al., 1997; Snijder and Spaan, 2006; 
Snijder and Meulenberg, 1998)], and the remaining seven 
ORFs (2a, 2b and 3-7) encode structural proteins of the virus. 
These include four membrane glycoproteins GP2 (25 kDa), 
GP3 (3642 kDa), GP4 (28 kDa) and GP5 (30-44 kDa), respec 
tively encoded by ORFs 2b, 3, 4, and 5, tWo unglycosylated 
membrane proteins E (8 kDa) and M (17 kDa) encoded by 
ORFs 2a and 6, and the phosphorylated nucleocapsid protein 
N (14 kDa) encoded by ORF7 (de Vries et al., 1992; Snijder 
et al., 1999; Wieringa et al, 2002). 
Prevention and control of EVA in North America is 
achieved by vaccination of horses With the modi?ed live virus 
vaccine strain of EAV (ARVAC®, Fort DodgeAnimal Health; 
Moore, 1986). Although the current modi?ed live virus 
(MLV) vaccine against EVA is safe and ef?cacious, there is 
resistance to using it in horses in many countries (eg Euro 
pean Union) regardless of the seroprevalence of EAV infec 
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2 
tion. One of the major concerns is the safety of the current 
MLV vaccine in pregnant mares, in particular the ability of the 
attenuated virus to cross the placenta and infects the unborn 
foal. The vaccine is only recommended for use in stallions 
and nonpregnant mares. It is not recommended for use in 
pregnant mares, especially during the last tWo months of 
gestation, or in foals less than 6 Weeks of age, unless they are 
at high risk of natural exposure. Furthermore, horses that are 
vaccinated With the current MLV cannot be distinguished 
from naturally infected animals. FolloWing the recent multi 
state EVA occurrence in the United States there is a strong 
industry demand for a marker vaccine to distinguish vacci 
nated animals from the naturally infected animals, as Well as 
to develop a MLV vaccine that is totally safe for use in 
pregnant mares. Thus, there remains a need in the art for novel 
means for control of outbreaks of EAV. The advent of recom 
binant DNA technology has helped to develop neW genera 
tion vaccines against a number of veterinary pathogens. 
These include live-vectored vaccines, gene deletion mutants 
and DNA vaccines. 
SUMMARY OF THE INVENTION 
To solve the aforementioned problems, there is provided an 
isolated polynucleotide molecule comprising a DNA 
sequence Which encodes an infectious RNA molecule encod 
ing a modi?ed live virus vaccine strain of an Equine arteritis 
virus. That polynucleotide sequence is derived from an 
Equine arteritis virus modi?ed live virus vaccine strain (AR 
VAC®, Fort Dodge Animal Health). In one embodiment, the 
polynucleotide sequence is SEQ ID NO:1 or a degenerate 
variant thereof. Vectors, including plasmid vectors, compris 
ing the polynucleotide molecule are provided. Still further, an 
isolated infectious RNA molecule encoded by the isolated 
polynucleotide molecule is provided, Which encodes a modi 
?ed live virus vaccine strain of the Equine arteritis virus. 
In another aspect, there is provided an isolated polynucle 
otide molecule comprising a DNA sequence Which encodes 
an infectious RNA molecule encoding an Equine arteritis 
virus, Wherein the DNA sequence is SEQ TD NO:2 or a 
degenerate variant thereof. In this embodiment, a silent point 
mutation is introduced, alloWing recognition and distinguish 
ing the sequence from the parent strain Equine arteritis virus 
or other strains of the virus. Vectors, host cells transfected 
With the polynucleotide molecule, and infectious RNA mol 
ecules encoded by the polynucleotide molecule are provided 
also. 
These and other embodiments, aspects, advantages, and 
features of the present invention Will be set forth in the 
description Which folloWs, and in part Will become apparent 
to those of ordinary skill in the art by reference to the folloW 
ing description of the invention and referenced draWings or by 
practice of the invention. The aspects, advantages, and fea 
tures of the invention are realiZed and attained by means of the 
instrumentalities, procedures, and combinations particularly 
pointed out in the appended claims. Various patent and non 
patent citations are discussed herein. Unless otherWise indi 
cated, any such citations are speci?cally incorporated by ref 
erence in their entirety into the present disclosure. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The accompanying draWings incorporated in and forming 
a part of the speci?cation, illustrate several aspects of the 
present invention, and together With the description serve to 
explain the principles of the invention. In the draWings: 
FIG. 1 presents a schematic in How diagram form of a 
cloning strategy for constructing a full-length infectious 
cDNA clone of the Equine arteritis virus modi?ed live vac 
cine strain (ARVAC®); and 
US 8,012,735 B2 
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FIG. 2 shows immuno?uorescent staining of BHK-21 cells 
transfected with in vitro transcribed RNA from the cDNA 
clone shown in FIG. 1. 
DETAILED DESCRIPTION OF THE 
ILLUSTRATED EMBODIMENTS 
In the following detailed description of the illustrated 
embodiments, reference is made to the accompanying draw 
ings that form a part hereof, and in which is shown by way of 
illustration, speci?c embodiments in which the invention may 
be practiced. These embodiments are described in su?icient 
detail to enable those skilled in the art to practice the inven 
tion. Also, it is to be understood that other embodiments may 
be utiliZed and that process, reagent, software, and/or other 
changes may be made without departing from the scope of the 
present invention. 
EXAMPLE 1 
FIG. 1 shows in ?ow diagram the strategy employed for 
construction of a full-length infectious cDNA clone of EAV 
MLV. The experimental details for this strategy have been 
previously set forth (Balasuriya et al., 2007; incorporated 
herein by reference). Brie?y, the pTRSB plasmid sequence 
(McKnight et al., 1996) used in making in the virulent 
pEAVrVBS infectious cDNA clone (Balasuriya et al., 2007; 
GenBank accession no. DQ846751) was used as the back 
bone to construct the EAV MLV clone. 
The viral RNA of EAV MLV strain (ARVAC®, Fort Dodge 
Animal Health) was RT-PCR ampli?ed using four pairs of 
synthetic oligonucleotide primers (a & b, c & d, e & f, and g 
& h), designed according to the EAV MLV nucleotide 
sequence (GenBank accession no. EU586275) to obtain four 
overlapping fragments (termed AB, CD, EF, and GH). Long 
PCR was carried out according to the manufacturers instruc 
tions with the Expand Long Template PCR system (Boe 
hringer Mannheim). The primers used are set forth in Table l . 
TABLE 1 
20 
25 
30 
35 
4 
With reference to FIG. 1, in step 1 a shuttle vector 
pBluEAVrVBSQihoI-EcoRV) was constructed by replacing 
the fragment XhoI-EcoRV of the plasmid pBlu2SKP with the 
fragment XhoI-EcoRV of the full-length clone pEAVrVBS. 
Next (step 2), the fragment AB was digested with restriction 
enZymes XbaI and EcoRV and then cloned into the shuttle 
vector pBluEAVrVBS(XhoI-EcoRV) which was also cut 
with the same restriction enZymes, to obtain the recombinant 
plasmid pBluEAVMLV(XhoI-EcoRV). In step 3, the plasmid 
pBluEAVMLVQihoI-EcoRV) was digested with restriction 
enZymes XhoI and EcoRV and then cloned into the full 
length clone pEAVrVBS which was also cut with the same 
restriction enZymes, to obtain the recombinant plasmid 
pEAVrVBSMLV(XhoI-EcoRV). 
The fragment GH was digested (step 4) with restriction 
enZymes BamHI and XhoI and then cloned into the plasmid 
pEAVrVBSMLV @(hoI-EcoRV) which was also digested 
with the same restriction enZymes, to obtain the recombinant 
plasmid pEAVrVBSMLVQ(hoI-EcoRV&BamHI-Xhol). 
Following, (step 5) the fragment EF was digested with restric 
tion enZymes BlnI and BamHI and then cloned into the plas 
mid pEAVrVBSMLVQ(hoI-EcoRV&BamHI-Xhol) which 
was also digested with the same restriction enZymes, to obtain 
the recombinant plasmid pEAVrVBSMLV(XhoI 
EcoRV&BlnI-XhoI). Finally, in step 6, the fragment CD was 
digested with restriction enZymes EcoRV and BlnI and then 
cloned into the plasmid pEAVrVBSMLV(XhoI 
EcoRV&BlnI-XhoI) which was also cut with the same 
restriction enZymes, to obtain the full-length clone 
pEAVrMLV. Following assembly, the EAV MLV cDNA 
(SEQ ID NO: 1) was immediately downstream of a T7 pro 
moter for generation of full-length in vitro transcripts of EAV 
MLV. 
EXAMPLE 2 
Once assembly of the full-length clone was complete, its 
authenticity was con?rmed by sequencing. That sequence is 
Primers used for reverse transcription and PCR 
amplification of the EAV MLV (ARVAC) fragments AB, CD, EF and GH. 
Table l . Primers for RT-PCR amplification of the 
EAV MLV vaccine strain (ARVACC) 
Digested 
with 
Primers for Primers for PCR restriction 
Fragment reverse transcription Forward Primer Reverse Primer enzymes 
Fragment 5 ‘ GTCATCATCAGTGAG Primer a Primer b XbaI + 
AB GGCAG3 ‘ GATTAATACGACTCACT CAGCGGCAGTGAT ECORV 
(SEQ ID NO: 5) ATAGCTCGAAGTGTGTA GTAG3 ‘ 
TGGTG3 ‘ (SEQ ID NO: '7) 
(SEQ ID NO: 6) 
Fragment 5 ‘ CCCCCGCGTTTGGTGA Primer c Primer d EcoRV + 
CD ATGC3 ‘ 5 ‘ TGCTTGTTCCATCTGG 5 ‘ TCTCCAGGTCTGT Blnl 
(SEQ ID NO: 8) TCTG3 ‘ TTCAAGG3 ‘ 
(SEQ ID NO: 9) (SEQ ID NO: 10) 
Fragment S‘ACTTCTGTTGAGCTGA Primer e Primer f Blnl + 
EF GGAG3 ‘ S‘ATTAGGAGCATTCTGG 5 ‘ACGCGACTCAGT BamHI 
(SEQ ID NO: 11) GCACC3 ‘ GTCTCAGG3 ‘ 
(SEQ ID NO: 12) (SEQ ID NO: 13) 
Fragment 5 ‘ GCACTCAGCTAGTAG Primer g Primer h BamHI + 
GH ACATCCTCGAGTTTTTT S‘TATTCTCGTCCGGTAGS ‘GCACTCAGCTAG XhOI 
TTTTTTTTTTTTTTGGTT GTTCG3 ‘ TAGACATCCTCG3‘ 
CCTGGGTGGCTAATAAC (SEQ ID NO: 15) (SEQ ID NO: 16) 
(SEQ ID NO: 14) 
US 8,012,735 B2 
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set forth herein as SEQ ID NO: 1. The cloned virus sequence 
(EAVrMLV) had 100% nucleotide identity to the master 
sequence of the parental MLV vaccine strain (GenBank 
accession no. EU586275). 
EXAMPLE 3 
Plasmid containing the full-length sequence of the MLV 
vaccine (pEAVrMLV; SEQ ID NO: 3; GenBank Accession 
No. EJ798195) Was XhoI-lineariZed and in vitro transcribed 
(IVT) RNA Was generated for electroporation into baby ham 
ster kidney cells (BHK 21 ; ATCC CCL10) according to pub 
lished methods (Balasuriya et al., 1999). The electroporated 
cells Were seeded onto culture plates and incubated at 370 C. 
until complete cytopathic effect (CPE) Was observed to con 
?rm infectivity. When 100% CPE Was observed the tissue 
culture ?uid Was harvested and stored at —800 C. 
EXAMPLE 4 
The infectivity of the IVT RNA Was con?rmed also by 
indirect immuno?uorescence (IFA; FIG. 2; see Balasuriya et 
al., 2007) to detect viral protein synthesis in BHK-21 cells 
transfected With synthetic full-length RNA. Electroporated 
cells Were plated directly onto chamber slides and incubated. 
The cells Were labeled With anti-nsp1 monoclonal antibody 
12A1 (Mab; FIG. 2b) and anti-nucleocapsid MAb 3E2 (FIG. 
2d) at 24 hours post transfection. Mock-transfected cells Were 
also stained With the same MAbs as controls (FIG. 211, 0). 
EXAMPLE 5 
To distinguish the cloned virus from the parental strain and 
from other ?eld and laboratory EAV strains, a silent point 
mutation (bp12,423 CQG) Was introduced into the cDNA 
clone described in Example 1, providing another infectious 
cDNA clone termed pEAVrMLVB (SEQ ID NO:4; GenBank 
Accession No.: EJ798196). The silent point mutation Was 
introduced using QuikChange II site-directed mutagenesis 
kit (Stratagene) and the mutagenesis primers 
EAV12423Pmut (5'-GATGCGGGTCCGGAAACCGC 
CCGCG-3': SEQ ID NO: 17) and EAV12423Nmut (5' 
CGCGGGCGGTTTCCGGACCCATC-3': SEQ ID NO:18). 
This clone contained a unique restriction site Bsp El (5' 
TCCGGA-3') at positions 12.419-12,424. This restriction site 
is lacking in pEAVrMLV. 
EXAMPLE 6 
A vaccine is formulated according to conventional meth 
ods, incorporating virus, plasmid, or other vectors comprising 
SEQ ID NO:1 and including acceptable carriers, including 
standard buffers, stabiliZers, diluents, preservatives, and the 
like, and may be formulated for extended release. Adjuvants 
or other immunomodulators may be included, such as Fre 
und’s complete or incomplete adjuvants and the like. An 
effective dosage of vaccine can be determined conventionally 
by methods knoWn to the skilled artisan, such as administer 
ing sequentially increasing doses of virus, plasmid, or vector 
comprising SEQ ID NO:1 and other additives as described to 
ascertain proper dosages and any side effects. Single or mul 
tiple administrations of vaccine are contemplated. Immune 
response to the vaccine is monitored by conventional meth 
ods, such as seroconversion and antibody titer post-vaccina 
tion. 
EXAMPLE 7 
A marker vaccine is formulated according to conventional 
methods, incorporating virus, plasmid, or other vectors com 
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6 
prising SEQ ID NO:2 and including acceptable carriers, 
including standard buffers, stabiliZers, diluents, preserva 
tives, and the like, and may be formulated for extended 
release. Adjuvants or other immunomodulators may be 
included, such as Freund’s complete and incomplete adjuvant 
and the like. An effective amount of vaccine can be deter 
mined conventionally by methods knoWn to the skilled arti 
san, such as administering sequentially increasing doses of 
virus, plasmid, or vector comprising SEQ ID NO:1 and other 
additives as described to ascertain proper dosages and any 
side effects. Single or multiple administrations of vaccine are 
contemplated. Immune response to the vaccine is monitored 
by conventional methods, such as seroconversion and anti 
body titer post-vaccination. The presence of the marker vac 
cine is detected by the presence of the unique restriction site 
Bsp EI (Example 5). This alloWs monitoring successful vac 
cination, even in the presence of antibody to Wild-type Equine 
arteritis virus. Even more, it is possible to differentiate vac 
cinated animals (by the described marker vaccine) from 
experimentally or naturally infected animals by detecting the 
mutation. 
One of ordinary skill in the art Will recogniZe that addi 
tional embodiments of the invention are also possible Without 
departing from the teachings herein. For example, the skilled 
artisan Will appreciate that it is noW possible, using the 
described cDNA clone of the modi?ed live virus of Equine 
arteritis virus, to provide a validated repository of seed virus 
for live virus vaccine production, ensuring a genetically 
homogenous virus stock. Further, the clone ?nds utility in 
development of mutations such as disable infectious single 
cycle (DISC) mutant, alloWing a combination of the safety of 
inactivated vaccines With the immunogenic activity of live 
viral vaccines. Still further, the cDNA marker clone (SEQ ID 
NO:4; Example 5) alloWs development of not only marker 
vaccines (Example 7), but also diagnostic assays for differ 
entiation of vaccinated animals from naturally infected ani 
mals. 
This detailed description, and particularly the speci?c 
details of the exemplary embodiments, is given primarily for 
clarity of understanding, and no unnecessary limitations are 
to be imported, for modi?cations Will become obvious to 
those skilled in the art upon reading this disclosure and may 
be made Without departing from the spirit or scope of the 
invention. Relatively apparent modi?cations, of course, 
include combining the various features of one or more ?gures 
or examples With the features of one or more of other ?gures 
or examples. 
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SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: 1s 
<211> LENGTH: 12704 
<212> TYPE: DNA 
<2l3> ORGANISM: Equine arteritis virus 
<4oo> SEQUENCE: 1 
gctcgaagtg tgtatggtgc catatacggc tcaccgccat atgcactgca agaattacta 6O 
ttcttgtggg cccctctcgg taaatcctag agggctttcc tctcgttatt gcgagattcg 120 
tcgttagata acggcaagtt ccctttctta ctatcctatt ttcatcttgt ggcttgacgg 180 
gtcactgcca tcgtcgtcga tctctatcaa ctacccttgc gactatggca accttctccg 240 
ctactggatt tggagggagt tttgttaggg actggtccct ggacttaccc gacgcttgtg 300 
agcatggcgc gggattgtgc tgtgaagtgg acggctccac cttatgcgcc gagtgttttc 360 
gcggttgcga aggagtggag caatgtcctg gcttgttcat gggactgtta aaactggctt 420 
cgccagttcc agtgggacat aagttcctga ttggttggta tcgagctgcc aaagtcaccg 480 


























